The increasing prevalence of drug-resistant pathogens is outpacing drug discovery efforts [1][2][3][4] , undermining the effectiveness of current antibiotics and jeopardizing many of the life-saving medical interventions that are now taken for granted 5 . The development and use of increasingly comprehensive infectious disease diagnostics will be important for controlling this global threat [6][7] [8] .
The increasing prevalence of drug-resistant pathogens is outpacing drug discovery efforts [1] [2] [3] [4] , undermining the effectiveness of current antibiotics and jeopardizing many of the life-saving medical interventions that are now taken for granted 5 . The development and use of increasingly comprehensive infectious disease diagnostics will be important for controlling this global threat [6] [7] [8] .
The laboratory diagnosis of infectious diseases is currently carried out using primarily culture-based methods that generate results in days, which is often too late to affect the initial selection of appropriate antimicrobials 8 . Given that they identify microbial nucleic acid (NA) sequences directly in clinical samples, NA amplification tests (NAATs) promise rapid molecular diagnostics (MDx) results [9] [10] [11] [12] , sometimes in less than an hour 13, 14 . However, existing NAAT technologies have two fundamental limitations that have impeded their adoption, specifically in detecting the full repertoire of drug-resistance -conferring mutations carried by multidrug-resistant (MDR) pathogens [15] [16] [17] . The first is their limited level of multiplexing, defined as the maximum number of sequences (or strains) that can be detected in one reaction, typically less than eight, using multicolor fluorophore techniques 18 . The second is their low base-calling resolution and accuracy for detecting single-nucleotide polymorphisms (SNPs) or other mutations. Using allele-specific primers 19 or fluorogenic probes 18, 20 , it is possible to assess localized sequence variations (typically three to six nucleotides), but neither the exact base change nor the precise coordinate can be retrieved with high confidence.
There have been attempts to address these challenges, such as designing fluidic systems that are capable of executing multiple single-plex NAATs [21] [22] [23] [24] or incorporating end-point microarrays 25 . Such tactics enhance multiplexing (up to 50) , but come at the expense of losing real-time detection (and quantification) capability 26 and of adding to the complexity and cost of both the consumable and the instrument. Recently, next-generation DNA sequencing (NGS) platforms 27 were used to identify MDR pathogens. NGS results can comprehensively identify the complete genomes of tens of pathogens in a run. However, they have complex workflows with slow turnaround times (>0.5 d), making them more suitable for archival and surveillance functions than for infectious disease MDx that necessitates rapid methods to diagnose, treat and monitor disease progression in critically ill patients.
We developed a multiplexed NAAT and a semiconductor biochip that, in a single sample, is capable of rapidly amplifying, detecting and quantifying hundreds of DNA or RNA sequences, including species-specific signatures, genotypes and mutations that confer drug resistance. This miniaturized and disposable (single-use) biochip is fabricated using sub-micron complementary metal oxide semiconductor (CMOS) processes 28 and includes 1,024 independent DNA biosensors with thermocycling capabilities. The DNA biosensors Multiplexed identification, quantification and genotyping of infectious agents using a semiconductor biochip employ inverse fluorescence techniques 29 to interrogate the multiplex NAAT in parallel and in real time. In contrast to other multiple single-plex systems [21] [22] [23] [24] or end-point microarrays 25 , the NAAT method reported here is multiplex and homogeneous (closed tube), requiring no washing or reagent addition after the extracted NA sample enters its reaction chamber. As a result of full CMOS chip-level integration, the system does not need an imager, complex optics or a bulky thermocycling system.
To demonstrate the feasibility and performance of this platform, we report results for two MDx panels. In the first, multiple viral RNAs and DNAs from respiratory tract pathogens were identified and quantified, and in the second, >50 antibiotic-resistance-conferring mutations across multiple genes of the Mycobacterium tuberculosis (MTB) genome were detected.
RESULTS

NAAT platform
The main components of the NAAT platform include a fluidic chamber in which the NA extracted from clinical samples is subjected to a multiplex PCR process, a solid-phase oligonucleotide DNA array with addressable pixels, each containing sequences complementary to specific parts of PCR amplicons, and an embedded biosensor array (biochip [30] [31] [32] ) capable of detecting DNA-DNA hybridization events at every pixel throughout the multiplex PCR (Fig. 1) .
Three integrated functions enable NA detection: amplification of NA regions of interest (ROIs) in the fluidic chamber; use of the biochip to monitor the generation of amplicons during PCR; and sequence identification through probe-amplicon solid-phase melting-curve analysis (MCA) 33, 34 at the end of PCR. The ROIs consist of signature sequences that are unique to a particular species, genotype or gene or genomic coordinates that encompass mutations (SNPs, insertions and deletions) that confer a medically relevant phenotype (for example, drug resistance) (Fig. 1) . Thus, the in-pixel probe sequences are either aimed at capturing signature sequences or designed as mutation-specific pairs to discriminate between wild-type (WT) and mutant (MT) strains through solidphase MCA.
To obtain optimal functioning, we asymmetrically amplified each amplicon in the fluidic chamber by adjusting the concentration of the forward PCR primer (p f ) to be greater than that of the reverse primer (p r ) 35 . This enhances solid-phase hybridization kinetics and MCA accuracy by generating excess single-stranded DNA (ssDNA) amplicons, denoted by a f . In addition, the depletion of p r during PCR cycles can serve as a means to measure amplicon generation. As a result, probes with sequence complementary to p r are included to monitor the [p r ] value at every cycle and estimate initial template concentration using threshold cycle (C t ) methods 36, 37 (Supplementary Note 1).
Real-time transduction using an inverse fluorescence method Realization of this multiplex NAAT method requires a homogeneous (closed-tube) assay with a real-time transduction method to detect, in parallel, solid-phase hybridization kinetics and a biochip in the reaction chamber that is operational during PCR.
Several real-time transduction methods have been reported that detect biomolecular capture events on solid-phase surfaces using optical 29, 38, 39 , electrochemical 26, 40, 41 or electromechanical 42, 43 techniques. Although some of these methods are common in life science research (for example, surface plasmon resonance 39 ), their adoption in genomics and specifically NAAT has been limited. This is a result of a variety of reasons, predominantly their limited sensitivity versus 'gold-standard' fluorescence techniques, incompatibility with highdensity arrays 44 or limited operating temperature range.
To overcome these limitations, we use an inverse fluorescence transduction (IFT) method with real-time (and solid-phase) detection capabilities. In IFT, the capture probes on the array include fluorophores, whereas the targets are labeled with non-radiating quenchers (Fig. 2) . Target-probe hybridization brings the quencher (acceptor) into proximity (<3 nm) with the fluorophore (donor) and 'turns off ' radiating relaxation through static or dynamic fluorescence
Temperature ( The closed-tube platform consists of a fluidic chamber affixed to a DNA biosensor array. The chamber receives microbial NA extract and multiplex PCR reagents and supports solution-phase amplification. DNA capture probes with specific thermodynamic affinity to amplified ROIs in the microbial genome functionalize individual biosensor pixels of the biochip. (b) Each ROI is asymmetrically amplified in multiplex with excess forward primers (p f ) and limiting reverse primers (p r ) to create, in part, ssDNA amplicons (a f ). (c) After amplification, ssDNA amplicons bind to specific capture probes on pixels during the real-time hybridization (HYB) step. The thermodynamic stability of these associations is tested during the MCA (MELT) step, in which dissociation of the solid-phase DNA duplex is monitored by the biosensor pixel versus temperature. For example, probe pairs can be allocated to a mutation to facilitate base calling by differentiating between the WT and MT strain melting curve signatures.
resonance energy transfer (FRET) quenching mechanisms 45 . Unlike conventional genomics arrays that employ fluorescently labeled targets 44 (Fig. 2a) , hybridization IFT results in a decrease in a probe's signal (hence the term inverse). Notably, the solution in IFT contains quenchers, not fluorophores, generating little background signal. Thus, presence of the solution does not impede real-time optical measurements of hybridization kinetics.
We implemented two approaches to create quencher-labeled amplicons during PCR (Supplementary Note 2) . In the first approach, forward primers were synthesized with quenchers at their 5′ end to create end-labeled ssDNA amplicons. We were able to further enhance transduction efficiency by including additional bases at the 3′ end of the probe complementary to the forward primer's 5′ end and promote contact quenching (Fig. 2b) . In the second approach, quencher-labeled deoxynucleotide triphosphates (Q-dNTPs) plus Taq polymerases capable of incorporating modified bases 46 were used in the master mix to produce stochastically quencher-labeled ssDNA amplicons (Fig. 2c) . Although both of these approaches enable IFT, there are important tradeoffs. In the case of end-labeled ssDNA amplicons, conventional PCR master mixes and enzymes can be used, but involved probe design is required. On the other hand, using QdNTPs increases the number of quenchers per amplicon, which improves transduction gain and requires very simple probe structures. However, a surfeit of Q-dNTPs in PCR and incorporation of modified bases were able to inhibit polymerase processivity, thereby reducing PCR efficiency and yield (Supplementary Note 3) .
Real-time DNA probe design Specific oligonucleotide IFT probe structures (Fig. 3a) were designed to assess the molecular kinetics and thermodynamics of probe-amplicon hybridization. These structures included an immobilization linker and a dual-fluorophore construct at their 5′ and 3′ termini, respectively. The intervening central section, between 15-35 nucleotides, had the unique capture sequence complementary to the target.
The dual-fluorophore construct included FAM (fluorescein) and TAM (tetramethylrhodamine) dyes separated by six thymidine bases. This arrangement offers two key advantages over conventional single-donor FRET constructs. First, as a result of the overlap between the FAM emission and TAM excitation spectra, a FRET efficiency of >85% was achievable for the molecular distance of six thymidine bases (~3.5 nm). As a result, the conjugated FAM-TAM construct exhibited a large Stokes shift of 88 nm with the excitation characteristics of FAM (peak excitation wavelength, λ x = 495 nm) and the emission characteristics of TAM (peak emission wavelength, λ e = 583 nm). Moreover, both FAM and TAM were able to interact with broadly absorbing quenchers to efficiently turn off emission. This resulted in both a larger effective quenching distance and a wider quenching spectrum (Supplementary Note 4) .
IFT probes can detect both the association (capture) and dissociation (detachment) of probe-amplicon duplexes. However, the measured signals from these cases contain dissimilar information. The capture signal is primarily a function of [a f ] and array surface chemistry 29 , as it is driven by the hybridization association constant, k on , a parameter that is less sequence specific 47 . The detachment or 'melting' signal, on the other hand, is mainly set by k off , the dissociation constant, a parameter that is a function of the base pairing in the primer-probe duplex and is strongly sequence dependent. Thus, we took advantage of the melt signal to verify the amplicon sequence through MCA and used the capture signal for quantification during PCR cycles. advance online publication nature biotechnology
A r t i c l e s
CMOS biochip
The function of the CMOS biochip is to detect the real-time IFT signals generated by the oligonucleotide array printed on its surface while controlling the temperature of the fluidic chamber to enable PCR or solid-phase MCA (Fig. 3) . The disposable NAAT module was assembled by mounting the CMOS biochip on an electronic printed circuit board (PCB) board and mounting an optically transparent plastic fluidic cap on its top to form a ~40-µl flow-through chamber, exposing only the array surface to the fluid (Fig. 3d) . The multiplex PCR mix and extracted NA sample were introduced through a sealable fluidic port before initiation of the NAAT process. This CMOS biochip includes an embedded fluorescence sensor array with 32 × 32 (1,024) addressable locations (pixels) with a 100-µm pitch (Fig. 3e,f) . Each pixel includes IFT probes in addition to a dedicated photodetector and electronic readout circuits to both acquire and digitize the fluorescence emission photon flux. IFT measurements are conducted at any point simply by activating an external LED excitation light source that is synchronized with the capture instruction sent to the chip.
The in-pixel photodetector includes a photosensor element to convert the emitted photon flux (F e ) from the IFT probes to a detectable photocurrent, I ph (Fig. 3b) . The photosensor element is a 50 µm × 50 µm N well -P sub planar embedded photodiode 48 with a junction depth of ~1.5 µm, external quantum efficiency (QE) of >0.36 e -/ph in the 480-to 800-nm spectrum, and dark currents (I d ) of 20 fA and 5.5 pA at 30 °C and 90 °C, respectively. Only 25% of the pixel comprised the photodiode, and the rest included a tunable-gain ∆Σ photocurrent sensor 49 to both amplify and digitize I ph (Fig. 3g) . The overall sensor array has an adjustable speed of 1-50 reads per second. The photosensor is implemented to be shot noise limited for photon flux densities of >10 10 photons/cm 2 /s and can be programmed to detect a maximum photon flux density of ~10 16 Although the detection performance of the photodetector, including its sensitivity and dynamic range, was more than adequate for fluorescence (and IFT) measurements, the photodetector lacked the correct wavelength selectivity to properly block LED excitation photon flux (F x ). As a result, a planar multi-dielectric emission filter 50 with optical density (OD) >3.5 was designed and integrated on top of the CMOS chip (Fig. 3c) to reject F x while passing F e .
To enable thermocycling and solid-phase MCA, we implemented a resistive heater and multiple temperature sensors in the CMOS die. On-chip temperature sensors monitored temperature-dependent I d and used the measured value to estimate the temperature of the fluid with an accuracy of ±0.3 °C in the temperature range 50-95 °C across the array. The cooler in this system was a thermal assembly with a heat sink attached to the thermally conductive chip substrate through the PCB of the module. These elements are programmable and provide heating/cooling rates of ±4 °C/s for the fluid in the reaction chamber.
Multiplex pathogen detection and quantification
To demonstrate the pathogen detection capabilities of this NAAT platform, we carried out parallel identification and quantification of six respiratory tract pathogens: four RNA viruses (influenza A, influenza B, respiratory syncytial virus and parainfluenza virus 2) and two DNA viruses (adenovirus C and adenovirus E).
In this multiplex test, the CMOS biochip fluidic chamber included a one-step RT-PCR mix, NA extracted from a clinical sample, positive control (a synthetic portion of the polio 1 genome) and eight quencher-labeled primer pairs. We immobilized IFT probes on 249 of the 1,024 pixels of the CMOS biochip to detect the presence of each ssDNA amplicon at the end of multiplex PCR and to monitor the depletion of each reverse primer for threshold-based quantification. Across the array, there were 5 identical IFT probes per target for redundancy and 15 auxiliary control probes, all of which were distributed uniformly to accommodate any manufacturing variations.
We tested five different samples, run in triplicate with variable concentrations of FluA RNA virus (~100 to 100,000 copies/µl; Fig. 4a) . By monitoring the depletion of reverse primer (FluA), we were able to generate 'amplification curves' to estimate the initial template concentration (Fig. 4b) . As anticipated, the corresponding C t values were found to obey an inverse log-linear relationship with concentration (R 2 = 0.97 and C t = -3.46log 10 [C] + 40.63). It is important to reemphasize that the multiplex PCR process was monitored using IFT probes at different pixels; thus, we tracked amplification of all of the amplicons simultaneously, in true multiplex, without the need for additional chambers.
To detect with the highest level of specificity, we considered MCA in addition to presence or absence of the amplification curves (Fig. 4c) . A positive call was only declared when a valid amplification curve (C t < 40) and a valid melting curve were both simultaneously present for a given pathogen. For the validity of melting curves, the integral of the difference between the signal and negative control was used as the deciding metric with a threshold of 0.1. We used this approach for 11 anonymous patient samples (11 CMOS biochip experiments) that we also tested using a commercially available respiratory virus panel and instrument ( Fig. 4d and Reporting Summary). In these blinded tests, all 11 CMOS biochip results matched the outcome of the commercially available system (Fig. 4e,f) .
Detecting drug-resistance mutations in M. tuberculosis
To demonstrate the genotyping accuracy and multiplexing capabilities of this NAAT platform, we attempted to identify 54 antibioticresistance-conferring SNPs across 16 ROIs of the GC-rich (67% GC) MTB genome. These ROIs were located in six different MTB genes (rpoB, aphC, inhA, katG, gyrA and gyrB), and the selected SNPs conferred resistance to rifampicin, isoniazid or fluoroquinolones.
We designed and tested 104 IFT probes (Fig. 5) for their capacity to discriminate between WT and MT strains through the use of solid-phase MCA. The 16-plex asymmetric PCR adopted Q-dCTP to create quencher-labeled amplicons (denoted TB1 to TB16) during amplification. We immobilized IFT probes in 678 of the 1,024 pixels of the CMOS biochip, with 5 replicate probe pairs dedicated to identifying each SNP. To identify SNPs, we used the integral of the difference between the measured melting curves of the WT and MT probes for a particular base. Figure 5 shows the genotyping results of culture samples ( ~5,000 genomic copies/25 µl) comparing the drug-sensitive MTB WT strain (H37Rv) with 13 drug-resistant strains harboring SNPs that were sequence confirmed by NGS methods. Analysis of the melting curve data revealed that the platform not only accurately identified the WT base in the WT H37Rv genome at all of the positions assayed by the IFT probes, but also precisely identified every SNP when the mutated strains were assayed, even though some of these SNPs were in heavily GC-rich regions of the MTB genome with strong secondary structures.
To better illustrate the SNP detection versatility of the platform, let us discuss two contrasting IFT probe designs tailored to detect SNPs in ROIs with different secondary structures (Fig. 6a) : I572F SNP in rpoB (conferring resistance to rifampicin) and D94G SNP in gyrA (conferring resistance to fluoroquinolones). I572F (Fig. 6a) is in a random-coil region of the TB16 amplicon, whereas D94G (Fig. 6b) is buried in a stable hairpin (T m > 80 °C) of TB1, inaccessible to the probe. To detect I572F mutation, we designed a short probe with the SNP in the middle of the capture region. To detect D94G mutation, we designed probes with a capture sequence that extended beyond the SNP region and into a more accessible sequence of the amplicon. This 'anchor' acts as a kinetic enhancer by first binding and then bringing the rest of the probe into close proximity with its target, thereby facilitating formation of the thermodynamically favored structure (probe-amplicon duplex in this case).
DISCUSSION
We designed and developed a fully integrated CMOS biochip and a real-time transduction method to create a homogeneous (closedtube) NAAT platform that rapidly, accurately and in parallel identifies and quantifies multiple distinct NA sequences. Unlike conventional solution-based qPCR assays, where multiplex capacity is constrained by the availability of dyes with different spectral properties, our platform can detect hundreds of different sequences, limited by the number of pixels on the array and the redundancy required.
To demonstrate this multiplex capacity, we used this CMOS biochip to simultaneously identify multiple DNA and RNA respiratory viruses in the same clinical sample and quantify input NA over four orders of magnitude. To enable the platform to detect not only the infecting agent, but also the drug-resistance-conferring mutations it harbors, we applied solid-phase MCA to identify 54 SNPs located in six genes of the MTB genome that distinguish a drug-sensitive WT strain from drug-resistant strains.
Although this platform has multiplexing, time-to-result (<2 h), cost and workflow simplicity advantages over (and beyond) existing NAAT systems, it has certain limitations. First, it is hypothesis driven, that is, it identifies previously characterized target sequences or mutations known to confer a medically important phenotype. As such, it is not appropriate for the discovery of new microbes or new mutations, a task that is optimally suited for NGS platforms. Second, it is difficult to expand the genomic ROIs (and PCR multiplexing) beyond 100 and still ensure a fast time to result. This is a result of the maximum total concentration of amplicons that PCR chemistries can produce and its effects on the concentration-dependent kinetics of hybridization. Third, it is challenging to identify <20% MT in a WT background (heterogeneous samples) using MCA. Fourth, use of this platform at a point-of-care setting (for example, urgent care clinics or treatment stations) will require a sample-to-result workflow, calling for its integration with an NA extraction system. Despite these limitations, our platform's ability to quickly detect, genotype and quantify pathogenic DNA or RNA directly from a clinical sample meets the requirements of an NAAT for the diagnosis and management of patients with infectious diseases. Furthermore, manufacturing of CMOS biochips relies primarily on conventional semiconductor fabrication processes, which offer the highest level of reproducibility and robustness.
We believe that the use of platforms that enable detection of MDR pathogens will help to address the emerging antibiotic resistance TB1   TB2   TB3   TB4   TB5   TB6   TB7   TB8   TB9   TB10   TB11   TB12   TB13   TB14 TB15
TB16
Figure 5 MTB drug-resistance mutation (DRM) panel. Screening of 1 drug-sensitive WT strain (H37Rv) and 11 drug-resistant MT strains that harbor 13 NGS-confirmed SNPs that confer resistance to rifampicin, isoniazid or fluoroquinolones. Using differential MCA, we accurately identified the presence or absence of these mutations, as determined by the negative differential signal (score) obtained for each specified probe pair. For WT strain H37Rv, all ROIs were confirmed to be WT, as indicated by the positive differential signal obtained for all probe pairs.
problem by providing actionable data that enable healthcare providers to more precisely select drugs for treatment.
METhODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. 
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ONLINE METhODS
CMOS chip design and fabrication. The CMOS integrated circuit (IC) was designed at InSilixa using commercially available mixed-signal IC design CAD tools (Cadence) and was fabricated on 8-inch wafers using IBM's 0.25-µm RF CMOS process (4M/1P) at the IBM semiconductor foundry in Burlington, Vermont (Supplementary Note 5) . The integrated multi-dielectric emission filter was designed at InSilixa using Essential McLeod Software (Thin Film Center) and was fabricated, at the wafer level, by Viavi Solutions (Supplementary Note 6) . Wafer dicing, die attachment and wire bonding of the filter-coated dies on the disposable module FR4 PCB were performed at Corwil Technology Corporation.
Fluidic cap and NAAT module assembly. Fluidic caps were designed by InSilixa and manufactured by ALine. The optically transparent structure was constructed with multilayer polymethylmethacrylate (PMMA) material and bonded using a silicone pressure-sensitive adhesive (PSA) to form the resulting inlet/outlet fluidic channels as well as the fluidic chamber. The final fluidic cap structure was then bonded to the FR4 PCB with epoxy adhesive, in which a captive silicone O-ring creates and seals the ~40-µl fluidic chamber against the CMOS chip, at InSilixa. Provision was made in the design for both an inlet and outlet to introduce liquid (sample + reagents) to the fluidic reaction and to maintain internal pressure (Supplementary Note 7) .
Instrumentation and data acquisition. The CMOS biochip reader and interface electronics consist of a Spartan 6 XC6SLX16 FPGA (Xilinx), DACs, ADCs, a chip edge connector, and drivers for the LED electronics and heater module (Supplementary Note 8) . The electronic architecture and component assembly of the reader were designed using OrCAD (Cadence), and PCB manufacturing and assembly were done by Alterflex. In the reader, the single-bit output datastream from the CMOS IC pixels is fed into an array of software-implemented sinc 2 filters in the FPGA for decimation and filtering. Afterward, the FPGA transfers the filtered data, as time-stamped 32 × 32 frames, to a LabView-based application software through a USB interface.
Data signal processing.
The frame data and temperature profile (both set and measured) generated from the LabView application software are read and analyzed (including de-noising and feature extraction) using a custom MATLAB code (Mathworks) (Supplementary Note 9) . Surface functionalization. CMOS chips with a silicon dioxide top layer and bonded to the FR4 PCB were treated with oxygen plasma (600 W, 1 Torr, 120 °C, 3 min, float plate) followed by water (13 Torr, 120 °C, 5 min) for surface activation and silanol repopulation. Without breaking vacuum, the substrates were then treated with (3-glycidoxypropyl)trimethoxysilane (greater than 99% purity; Gelest) (0.5 Torr, 120 °C, 30 min) 51 . All steps were performed with a YES 1224P chemical vapor deposition instrument (Yield Engineering). After cooling in a humidity-controlled environment (20% relative humidity wafer drybox with continuous nitrogen purging), the functionalized substrates typically exhibited a water contact angle of 45° ± 5°, measured with a Rame-Hart Model 400 goniometer. Functionalized substrates were normally used within 3 d of preparation.
Probe printing onto the array. HPLC-purified synthetic DNA probes bearing hexylamine at the 5′ terminus and fluorescent label(s) at the 3′ terminus were procured from LGC BioSearch Technologies or Integrated DNA Technologies and reconstituted to 50 µM in pH 8.5 phosphate buffer. Piezo-type printing with a sciFLEXARRAYER SX (Scienion) was employed to deposit ~80-pl droplets onto individual 100-µm pixels. On-CMOS-chip fiducial alignment and realtime vision systems ensured sufficient drop placement accuracy and verification. Covalent coupling of each DNA probe to the functionalized surface was accomplished with overnight incubation at room temperature with 50% relative humidity. Excess unbound DNA probe was removed by extensive dilution/washing with aqueous buffer, and any unreacted epoxy groups were simultaneously rendered inert with a Tris-buffered solution containing ethanolamine. The fluorescent label of the printed DNA probes enabled post-printing confirmation of functional attachment. Printed CMOS biochips were stored in a desiccated nitrogen environment at 4 °C until assembly, typically within ~6 months.
In silico nucleic acid thermodynamic simulations. Oligonucleotide Modeling Platform (OMP) software (DNA Software) was used to simulate interactions between DNA-RNA and DNA-DNA sequences under assay-specific conditions for primer and probe design efforts. The software was configured to compute multistate equilibrium models for competing intermolecular and intramolecular interactions. Specifically, OMP was used to predict NA duplex formation and melt curves by performing nearest-neighbor thermodynamic calculations in the temperature range 45-95 °C. A suite of tools was created in Perl and MATLAB to streamline the computational procedures for the design of both multiplex PCR primer pairs and IFT probes (Supplementary Note 10) .
Multiplex PCR primer design. Primer design facilitated by OMP included the following steps: (i) select regions; for highly structured amplicons, local ROI unfolding energies were used to focus primer design on structurally accessible regions; (ii) ensure OMP predicts thermodynamically favorable primertemplate extension; (iii) ensure that the primer is predicted to primarily exist in a random-coil state; (iv) ensure that the specific region of the template, to which the primer binds, is accessible; in cases where no such region was identified, as much of the primer as possible was placed in a random-coil portion of the template; (v) eliminate primers that are capable of self-priming; (vi) eliminate amplicons that are capable of self-priming; and (vii) perform primer-dimer and primer-amplicon checks. Once candidate primers for the single-plex assays were designed, all possible pairs of primers were checked for their potential to form primer dimers and redesigned where necessary. The URP assay employed previously described primers, which were then subjected to this review (Supplementary Note 10) . Primers for the MTB assay were initially designed with Primer3 before undergoing the same review and refinement (Supplementary Note 10) . Primer candidates passing the in silico criteria were then experimentally qualified, first in single-plex and then in multiplex, for their ability to produce >10 nM quencher-labeled ssDNA.
IFT probe design. Three distinct probe categories were employed: (i) quantification probes to monitor depletion of the limiting primers during multiplex PCR; these probes were used only in the URP assay and are complementary to the limiting primer; (ii) detection probes to examine the presence or absence of the target; these probes were used mainly in the URP assay and contain additional bases at the 3′ end of the probe complementary to the excess primer 5′ end; and (iii) SNP identification probe pairs to detect mutations within ROIs. These probes were used in the MTB assay. In all cases, assay-specific physiochemical conditions (that is, salt conditions and temperature) were inputs to thermodynamic simulations. URP contrived samples. Synthetic target DNA was obtained from LGC BioSearch Technologies as PAGE-purified material provided in Tris-HCl pH 8.5 at 10 6 copies/µl. RNA was transcribed from synthetic DNA containing an SP6 promoter, DNase I digested, PAGE purified and provided in sodium citrate pH 6.4 at 10 6 copies/µl. Total NA extracts from cultured viral material containing whole viral genomes were used for on-chip experiments. Inactivated cultured virus was obtained from Zeptometrix. RNA and DNA was extracted from this material with the QIAamp Viral RNA Mini kit (80204, Qiagen) and the QIAmp DNA/RNA Mini kit (52904, Qiagen), respectively, following the manufacturer's instructions and quantified using qPCR or RT-qPCR as required. Total NA extracts from viral culture material were obtained from American Type Culture Collection (ATCC) and quantified using qPCR. Incoming or purified samples were aliquotted and stored at -80 °C (Supplementary Note 11) . 
Data exclusions
Describe any data exclusions. Any data, including physical, bio-physical, chemical, or biological extracted from any biochip or its components that failed to pass internal QC tests has been excluded. Our internal QC tests check/verify CMOS chip electrical/optical functionality (failure frequency < %1), surface functionalization and probe printing (failure frequency < 2%), biochip module assembly and fluidics integrity (failure frequency = 7%), and the NA extraction and NAAT amplification chemistry (failure < 3%).
NOTE: The above failure rates are estimations from early 2017, when the patient samples were tested on the prototype systems. These numbers, except CMOS biochip electrical/optical and surface functionalization failure rates, have been improved since then as our product development has progressed.
Replication
Describe whether the experimental findings were reliably reproduced.
Yes, the results were reliably reproduced.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
All experiments were done using randomly selected CMOS biochip devices without any pre-selection or sorting. Blind experiment were done for 11 patient samples. The other proof-of-principle experiments were done with known and prepared and qualified samples.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
The upper respiratory panel validation experiments using patient samples were done in a blinded fashion, i.e., the team members responsible for the biochip experiments and its data analysis were not aware of the results from the GenMark system. Once they made the determinations regarding the presence of a pathogen for all 11 experiments, they were made aware of the GenMark system results.
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Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
Materials and reagents
nature research | life sciences reporting summary No eukaryotic cell lines were used in this study.
Animals and human research participants
Policy information about studies involving animals; when reporting animal research, follow the ARRIVE guidelines
Description of research animals
Provide details on animals and/or animal-derived materials used in the study.
No animals were used in this study.
Policy information about studies involving human research participants
Description of human research participants
Describe the covariate-relevant population characteristics of the human research participants.
The patient samples were anonymous, archived remnant samples. We have no information regarding population characteristics of the patients, only prior test results.
